Vascular-targeted PDT (vPDT) has produced promising results in the treatment of many cancers, including drug-resistant ones, but little is known about its efficacy in lymphoma. Unfortunately, the lack of a specific therapeutic target and a hypoxic microenvironment for lymphoma jeopardizes the efficacy of vPDT severely. In this study, we designed a lymphoma tissue factor-targeted "O-evolving" strategy combining PDT with catalase and HMME-encapsulated, EGFP-EGF1-modified PEG-PLGA nanoparticles (CENPs) to boost PDT efficiency; this combination takes advantage of the low oxygen tension of lymphoma. In our results, CENPs accumulated effectively in the vascular lymphoma and , and this accumulation increased further with PDT treatment. Per positron emission tomography imaging, combining CENPs with PDT inhibited lymphoma glucose metabolism significantly. The expression of hypoxia-inducible factor (HIF)-1α in the entrapped catalase groups reduced markedly. These data show that the combined administration of PDT and CENPs can prompt tissue factor-cascade-targeted and self-supply of oxygen and that it has a good therapeutic effect on malignant lymphoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683716PMC
http://dx.doi.org/10.3389/fonc.2020.524712DOI Listing

Publication Analysis

Top Keywords

tissue factor-targeted
8
factor-targeted "o-evolving"
8
lymphoma
8
malignant lymphoma
8
pdt
6
"o-evolving" nanoparticles
4
nanoparticles photodynamic
4
photodynamic therapy
4
therapy malignant
4
lymphoma vascular-targeted
4

Similar Publications

Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies.

Cancer Immunol Immunother

January 2025

Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD, 20892, USA.

Tissue factor (TF) is a cell surface protein that plays a role in blood clotting but is also commonly expressed in many cancers. Recent research implicated TF in cancer proliferation, metastasis, angiogenesis, and immune escape. Therefore, TF can be considered a viable therapeutic target against cancer.

View Article and Find Full Text PDF

Tissue factor (TF) initiates local blood clotting and infiltration of tumor-associated macrophages, leading to tumor recurrence post-local ablation. Our study addressed inefficient cancer cell killing and immunosuppressive macrophage infiltration after percutaneous ethanol injection (PEI) in hepatocellular carcinoma (HCC). We evaluated the feasibility of F-radiolabeled polypeptide TF-targeted radioligand (tTF) as a PET tracer for assessing tumor response.

View Article and Find Full Text PDF
Article Synopsis
  • Shortwave-infrared (SWIR) imaging is suggested to improve contrast in fluorescence-guided surgery compared to near-infrared (NIR) imaging, but it has only been tested in animal studies so far.
  • The study aims to evaluate the benefits of SWIR imaging in clinical samples treated with the NIR dye cetuximab-IRDye800CW, focusing on tumor-targeted applications in penile and head and neck cancers.
  • Results indicate that while SWIR performs similarly to NIR in penile cancer samples, NIR outperforms SWIR in most criteria for head and neck cancer due to high background autofluorescence, suggesting that SWIR may enhance contrast in some situations but not universally across all clinical
View Article and Find Full Text PDF

Platinum-based chemotherapy is commonly used for treating solid tumors, but drug resistance often limits its effectiveness. Cancer-associated fibroblast (CAF)-derived extracellular vesicle (EV), which carry various miRNAs, have been implicated in chemotherapy resistance. However, the molecular mechanism through which CAFs modulate cisplatin resistance in oral squamous cell carcinoma (OSCC) is not well understood.

View Article and Find Full Text PDF

Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer.

Lab Invest

November 2023

Department of Pathology, Tri-Service General Hospital, Taipei, Taiwan; Institute of Pathology and Parasitology, National Defense Medical Center, Taipei, Taiwan. Electronic address:

Epithelial ovarian cancer (EOC) remains a significant cause of mortality among gynecologic cancers, with the majority of cases being diagnosed at an advanced stage. Before targeted therapies were available, EOC treatment relied largely on debulking surgery and platinum-based chemotherapy. Vascular endothelial growth factors have been identified as inducing tumor angiogenesis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!